Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04139317
Title Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1 >= 50%
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Capmatinib + Pembrolizumab

Pembrolizumab

Age Groups: senior | adult
Covered Countries ITA | FRA | ESP | DEU | CAN | BEL

Facility Status City State Zip Country Details
Novartis Investigative Site Wollongong New South Wales 2500 Australia Details
Novartis Investigative Site North Adelaide South Australia 5006 Australia Details
Novartis Investigative Site Shepparton Victoria 3630 Australia Details
Novartis Investigative Site Bruxelles 1000 Belgium Details
Novartis Investigative Site Liege 4000 Belgium Details
Novartis Investigative Site Yvoir 5530 Belgium Details
Novartis Investigative Site Quebec GIV 4G5 Canada Details
Novartis Investigative Site Ostrava Vitkovice 703 84 Czechia Details
Novartis Investigative Site Lille 59000 France Details
Novartis Investigative Site Strasbourg Cedex 67091 France Details
Novartis Investigative Site Toulouse 31400 France Details
Novartis Investigative Site Berlin 14165 Germany Details
Novartis Investigative Site Koeln 50937 Germany Details
Novartis Investigative Site Athens 11526 Greece Details
Novartis Investigative Site Thessaloniki 57001 Greece Details
Novartis Investigative Site Shatin, New Territories Hong Kong Details
Novartis Investigative Site Mumbai Maharashtra 401107 India Details
Novartis Investigative Site Kolkata West Bengal 700160 India Details
Novartis Investigative Site Delhi 110 085 India Details
Novartis Investigative Site Ancona AN 60126 Italy Details
Novartis Investigative Site Aviano PN 33081 Italy Details
Novartis Investigative Site Nagoya Aichi 466 8560 Japan Details
Novartis Investigative Site Yokohama-city Kanagawa 236 0051 Japan Details
Novartis Investigative Site Kuching Sarawak 93586 Malaysia Details
Novartis Investigative Site Kuala Lumpur 59100 Malaysia Details
Novartis Investigative Site Amersfoort 3813 TZ Netherlands Details
Novartis Investigative Site Breda 4819 EV Netherlands Details
Novartis Investigative Site Zwolle 8025 AB Netherlands Details
Novartis Investigative Site Badalona Catalunya 08916 Spain Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Valencia Comunidad Valenciana 46010 Spain Details
Novartis Investigative Site Barcelona 08041 Spain Details
Novartis Investigative Site Madrid 28040 Spain Details
Novartis Investigative Site Changhua 50006 Taiwan Details
Novartis Investigative Site Taichung 40705 Taiwan Details
Novartis Investigative Site Bangkok 10330 Thailand Details
Novartis Investigative Site Bangkok 10400 Thailand Details
Novartis Investigative Site Bangkok 10700 Thailand Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field